Skip to main content

Dr. Reddy's Laboratories announces the launch of Bivalirudin for Injection in the U.S. Market

 

Clinical courses

Dr. Reddy’s Laboratories Ltd.announced that it has launched Bivalirudin for
Injection, 250 mg/vial, a therapeutic equivalent generic version of Angiomax® (Bivalirudin) for Injection, approved by the U.S. Food and Drug Administration (USFDA).

The Angiomax® brand and generic had U.S. sales of approximately $198 million MAT for the most recent twelve months ending in March 2017 according to IMS Health*.

 

Dr. Reddy’s Bivalirudin Injection, 250 mg/vial, are available in packages of 10 single-dose vials.

Angiomax® is a registered trademark of The Medicines Company.

<< Back to Pharma News

Subscribe to PharmaTutor News Alerts by Email